APA (7th ed.) Citation

SE, P., S, D., RL, S., GP, D., JJ, S., ER, W., . . . AH, D. (2013). Efficacy of low-dose oral metronomic dosing of the prodrug of gemcitabine, LY2334737, in human tumor xenografts. Molecular cancer therapeutics, 12(4), 481. https://doi.org/10.1158/1535-7163.MCT-12-0654

Chicago Style (17th ed.) Citation

SE, Pratt, Durland-Busbice S, Shepard RL, Donoho GP, Starling JJ, Wickremsinhe ER, Perkins EJ, and Dantzig AH. "Efficacy of Low-dose Oral Metronomic Dosing of the Prodrug of Gemcitabine, LY2334737, in Human Tumor Xenografts." Molecular Cancer Therapeutics 12, no. 4 (2013): 481. https://doi.org/10.1158/1535-7163.MCT-12-0654.

MLA (9th ed.) Citation

SE, Pratt, et al. "Efficacy of Low-dose Oral Metronomic Dosing of the Prodrug of Gemcitabine, LY2334737, in Human Tumor Xenografts." Molecular Cancer Therapeutics, vol. 12, no. 4, 2013, p. 481, https://doi.org/10.1158/1535-7163.MCT-12-0654.